Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Commentary|Articles|August 5, 2026
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
Author(s)Ashling Wahner
Fact checked by: Riley Kandel
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Advertisement
Advertisement
Antibody-drug conjugates (ADCs) are diversifying the first- and subsequent-line breast cancer treatment arenas, but despite recent FDA approvals providing earlier access to these highly effective treatments, questions remain regarding appropriate decision-making in the second-line setting and beyond.
Related to this article
Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.
Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN Guidelines for select patients with previously treated breast cancer.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.
Andrew H. Ko, MD, discusses how TTFields works and data that supported the FDA approval of Optune Pax for patients with pancreatic cancer.
Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Advertisement
Advertisement